Increased markers of cardiac vagal activity in leucine-rich repeat kinase 2-associated Parkinson's disease.
Autonomic dysfunction
Deceleration capacity of heart rate
Heart rate variability
LRRK2
Parkinson’s disease
Rényi entropy
Journal
Clinical autonomic research : official journal of the Clinical Autonomic Research Society
ISSN: 1619-1560
Titre abrégé: Clin Auton Res
Pays: Germany
ID NLM: 9106549
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
03
04
2019
accepted:
10
08
2019
pubmed:
25
8
2019
medline:
21
10
2020
entrez:
25
8
2019
Statut:
ppublish
Résumé
Cardiac autonomic dysfunction manifests as reduced heart rate variability (HRV) in idiopathic Parkinson's disease (PD), but no significant reduction has been found in PD patients who carry the LRRK2 mutation. Novel HRV features have not been investigated in these individuals. We aimed to assess cardiac autonomic modulation through standard and novel approaches to HRV analysis in individuals who carry the LRRK2 G2019S mutation. Short-term electrocardiograms were recorded in 14 LRRK2-associated PD patients, 25 LRRK2-non-manifesting carriers, 32 related non-carriers, 20 idiopathic PD patients, and 27 healthy controls. HRV measures were compared using regression modeling, controlling for age, sex, mean heart rate, and disease duration. Discriminant analysis highlighted the feature combination that best distinguished LRRK2-associated PD from controls. Beat-to-beat and global HRV measures were significantly increased in LRRK2-associated PD patients compared with controls (e.g., deceleration capacity of heart rate: p = 0.006) and idiopathic PD patients (e.g., 8th standardized moment of the interbeat interval distribution: p = 0.0003), respectively. LRRK2-associated PD patients also showed significantly increased irregularity of heart rate dynamics, as quantified by Rényi entropy, when compared with controls (p = 0.002) and idiopathic PD patients (p = 0.0004). Ordinal pattern statistics permitted the identification of LRRK2-associated PD individuals with 93% sensitivity and 93% specificity. Consistent results were found in a subgroup of LRRK2-non-manifesting carriers when compared with controls. Increased beat-to-beat HRV in LRRK2 G2019S mutation carriers compared with controls and idiopathic PD patients may indicate augmented cardiac autonomic cholinergic activity, suggesting early impairment of central vagal feedback loops in LRRK2-associated PD.
Identifiants
pubmed: 31444591
doi: 10.1007/s10286-019-00632-w
pii: 10.1007/s10286-019-00632-w
doi:
Substances chimiques
LRRK2 protein, human
EC 2.7.11.1
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
603-614Références
J Electrocardiol. 2008 Mar-Apr;41(2):110-5
pubmed: 18328334
Exp Physiol. 2019 Jun;104(6):793-799
pubmed: 30861251
J Neural Transm (Vienna). 2015 Mar;122(3):419-25
pubmed: 25038873
Front Bioeng Biotechnol. 2014 Sep 09;2:34
pubmed: 25250311
Eur Neurol. 1987;26(2):104-12
pubmed: 3830206
J Neural Transm (Vienna). 1996;103(4):447-54
pubmed: 9617788
Mov Disord. 2017 Apr;32(4):610-614
pubmed: 28071824
Phys Rev Lett. 2002 Apr 29;88(17):174102
pubmed: 12005759
Parkinsonism Relat Disord. 2013 Oct;19(10):906-9
pubmed: 23764467
Europace. 2018 Jun 1;20(FI1):f129-f136
pubmed: 29106527
Eur J Neurol. 2000 Nov;7(6):667-72
pubmed: 11136353
Circ Res. 1980 May;46(5):606-11
pubmed: 7363410
Neurology. 2011 Jul 26;77(4):325-33
pubmed: 21753163
Lancet Neurol. 2003 Nov;2(11):669-76
pubmed: 14572735
Lancet. 2015 Aug 29;386(9996):896-912
pubmed: 25904081
Lancet. 2006 May 20;367(9523):1674-81
pubmed: 16714188
J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4
pubmed: 1564476
Diabetes Care. 2003 May;26(5):1553-79
pubmed: 12716821
Neurology. 2005 Sep 13;65(5):696-700
pubmed: 16157901
Neurosci Lett. 1995 Jan 2;183(1-2):27-31
pubmed: 7746479
JAMA Neurol. 2015 Jan;72(1):100-5
pubmed: 25401511
Physiol Meas. 2015 Apr;36(4):755-65
pubmed: 25798715
Lancet Neurol. 2008 Jul;7(7):583-90
pubmed: 18539534
J Cardiovasc Electrophysiol. 2005 Sep;16(9):954-9
pubmed: 16174015
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16842-7
pubmed: 16269541
Lancet Neurol. 2018 Apr;17(4):309-316
pubmed: 29456161
Hypertension. 2007 Jan;49(1):120-6
pubmed: 17101845
J Cardiovasc Electrophysiol. 2005 Aug;16(8):870-1
pubmed: 16101629
Mov Disord. 2016 Jun;31(6):889-97
pubmed: 26917005
J Neurosci. 2012 Feb 1;32(5):1602-11
pubmed: 22302802
J Neuroinflammation. 2016 May 24;13(1):122
pubmed: 27220776
J Appl Physiol (1985). 2014 Mar 1;116(5):495-503
pubmed: 24436294
J Mov Disord. 2016 May;9(2):97-103
pubmed: 27020456
Neurology. 2007 Oct 16;69(16):1580-4
pubmed: 17625107
Comput Biol Med. 2012 Mar;42(3):319-27
pubmed: 21511252
Nature. 2000 May 25;405(6785):458-62
pubmed: 10839541